Blood Transfusions Clinical Trials
A listing of Blood Transfusions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 153 clinical trials
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
- 17 views
- 19 Dec, 2022
- 20 locations
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
who are transfusion-dependent or present with symptomatic anemia.
- 1 views
- 21 Oct, 2022
- 12 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia
) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening
- 16800 views
- 22 Aug, 2022
- 7 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US
luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The
- 54541 views
- 22 Aug, 2022
- 9 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada
safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.  
- 23120 views
- 22 Aug, 2022
- 10 locations
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.
- 0 views
- 07 Oct, 2022
- 1 location
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
without a need for an intrauterine transfusion (IUT) throughout their entire pregnancy.
- 150 views
- 04 Oct, 2022
- 11 locations
![A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy](/media/imagery/259499.svg)
A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
are to assess the following for REGN7257: Clinical response over time Maintenance of response Impact on transfusion requirements Effect on blood counts and
- 0 views
- 16 Oct, 2022
- 9 locations
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis
hemochromatosis donors available for transfusion into other patients. Patients 15 years and older with diagnosed hemochromatosis or very high iron levels suggesting possible hemochromatosis may be eligible
- 114 views
- 25 Oct, 2022
- 1 location
Gastroschisis Outcomes of Delivery (GOOD) Study
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a …
- 408 views
- 21 Oct, 2022
- 22 locations